Status:
COMPLETED
Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial
Lead Sponsor:
Tulane University Health Sciences Center
Collaborating Sponsors:
Centers for Disease Control and Prevention
Conditions:
Malaria
Eligibility:
All Genders
21-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standar...
Detailed Description
This is a 2-stage, randomized crossover study of a 2100 mg AQ-13 dose in healthy volunteers. Fourteen healthy volunteers will be randomized to receive the drug either on an empty stomach or after a st...
Eligibility Criteria
Inclusion
- Healthy volunteers 21-45 years of age taking no chronic medications other than birth-control pills
Exclusion
- Pregnancy,
- Breast-feeding,
- Chronic disease
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00455494
Start Date
January 1 2005
End Date
December 1 2006
Last Update
December 7 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tulane-LSU General Clinical Research Center
New Orleans, Louisiana, United States, 70112